Letter to the Editor: SUN vs BEVþIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival.

M. Nuijten,G Mickisch

Letter to the Editor: SUN vs BEVþIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival.

2010

M. Nuijten
G Mickisch

Letter to the Editor: SUN vs BEV þ IFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival

Keywords:

Immunology
Alternative medicine
Medicine
Letter to the editor
Progression-free survival
Cancer research
Oncology
first line
Internal medicine
Text mining
significant difference

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations